Efficacy of telithromycin in community-acquired pneumonia caused by Legionella pneumophila.
Department of Antiinfectives and Pulmonary Clinical Development, Aventis, Mailstop BX2-312A, 200 Crossing Boulevard, Bridgewater, NJ 08807, USA.
C
C
Carbon
R
R
Nusrat
D000293:Adolescent; D000328:Adult; D017714:Community-Acquired Infections / Q000175:diagnosis / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007391:International Cooperation; D048628:Ketolides; D016952:Legionella pneumophila / Q000187:drug effects / Q000302:isolation & purification*; D007877:Legionnaires' Disease / Q000175:diagnosis / Q000188:drug therapy*; D018942:Macrolides / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D048628:Ketolides; D018942:Macrolides; C106791:telithromycin